PL3610026T3 - Cg0070 do leczenia raka pęcherza moczowego in situ opornego na bcg - Google Patents

Cg0070 do leczenia raka pęcherza moczowego in situ opornego na bcg

Info

Publication number
PL3610026T3
PL3610026T3 PL18784592.0T PL18784592T PL3610026T3 PL 3610026 T3 PL3610026 T3 PL 3610026T3 PL 18784592 T PL18784592 T PL 18784592T PL 3610026 T3 PL3610026 T3 PL 3610026T3
Authority
PL
Poland
Prior art keywords
situ
bladder carcinoma
resistant bladder
treating
treating bcg
Prior art date
Application number
PL18784592.0T
Other languages
English (en)
Inventor
Arthur KUAN
Original Assignee
Cg Oncology, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cg Oncology, Inc. filed Critical Cg Oncology, Inc.
Publication of PL3610026T3 publication Critical patent/PL3610026T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
PL18784592.0T 2017-04-14 2018-04-13 Cg0070 do leczenia raka pęcherza moczowego in situ opornego na bcg PL3610026T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762485805P 2017-04-14 2017-04-14
US201762500729P 2017-05-03 2017-05-03
PCT/US2018/027549 WO2018191654A1 (en) 2017-04-14 2018-04-13 Methods of treating bladder cancer

Publications (1)

Publication Number Publication Date
PL3610026T3 true PL3610026T3 (pl) 2025-07-28

Family

ID=63792825

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18784592.0T PL3610026T3 (pl) 2017-04-14 2018-04-13 Cg0070 do leczenia raka pęcherza moczowego in situ opornego na bcg

Country Status (9)

Country Link
US (3) US11338003B2 (pl)
EP (2) EP3610026B1 (pl)
JP (3) JP2020516590A (pl)
KR (1) KR20190134786A (pl)
CN (1) CN110573624A (pl)
AU (1) AU2018251987B2 (pl)
ES (1) ES3030923T3 (pl)
PL (1) PL3610026T3 (pl)
WO (1) WO2018191654A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11497781B2 (en) 2016-03-10 2022-11-15 Cg Oncology, Inc. Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor
AU2018251987B2 (en) 2017-04-14 2024-11-28 Cg Oncology, Inc. Methods of treating bladder cancer
WO2019093435A1 (ja) * 2017-11-08 2019-05-16 国立大学法人 鹿児島大学 安全を確保しながら転移性がんまで効果的に治療可能な、搭載する免疫誘導遺伝子の最適発現レベルを与える発現制御システムを有する腫瘍溶解性ウイルス（腫瘍溶解性免疫治療）
WO2020014543A2 (en) 2018-07-11 2020-01-16 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
US20200222477A1 (en) * 2019-01-10 2020-07-16 Trizell Ltd. Method to Curtail the Progression of Non-Muscle Invasive Bladder Cancer To Muscle-Invasive Cancer
WO2020176809A1 (en) 2019-02-27 2020-09-03 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
EP4058578A2 (en) 2019-11-12 2022-09-21 Actym Therapeutics, Inc. Immunostimulatory bacteria delivery platforms and their use for delivery of therapeutic products
IL300447A (en) 2020-08-12 2023-04-01 Actym Therapeutics Inc Bacteria-based ingredients that stimulate the immune system, treatments and platforms for delivering RNA
JP2024542173A (ja) 2021-11-09 2024-11-13 アクティム・セラピューティクス・インコーポレイテッド マクロファージを処置に適している表現型に変換するための免疫刺激細菌および処置のための対象の同定のためのコンパニオン診断法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4590071A (en) 1984-09-25 1986-05-20 Xoma Corporation Human melanoma specific immunotoxins
US7001764B2 (en) 1995-06-27 2006-02-21 Cell Genesys, Inc. Compositions comprising tissue specific adenoviral vectors
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6432700B1 (en) 1997-03-03 2002-08-13 Cell Genesys, Inc. Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same
CA2283231C (en) 1997-03-03 2008-05-20 Calydon, Inc. Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same
AU2003252891B2 (en) 1998-09-10 2006-06-01 Cold Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
US6900049B2 (en) 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US6495130B1 (en) 1998-12-30 2002-12-17 Calydon, Inc. Target cell-specific adenoviral vectors containing E3 and methods of use thereof
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
AU784012B2 (en) 1999-08-24 2006-01-12 E. R. Squibb & Sons, L.L.C. Human CTLA-4 antibodies and their uses
US7048920B2 (en) 2000-03-24 2006-05-23 Cell Genesys, Inc. Recombinant oncolytic adenovirus for human melanoma
US6692736B2 (en) 2000-03-24 2004-02-17 Cell Genesys, Inc. Cell-specific adenovirus vectors comprising an internal ribosome entry site
CA2404235C (en) 2000-03-24 2010-09-21 Cell Genesys, Inc. Cell-specific adenovirus vectors comprising an internal ribosome entry site
AU2001273096B8 (en) 2000-06-28 2005-10-13 Dana-Farber Cancer Institute, Inc. PD-L2 molecules: novel PD-1 ligands and uses therefor
US7452535B2 (en) 2002-04-12 2008-11-18 Medarex, Inc. Methods of treatment using CTLA-4 antibodies
MXPA05006828A (es) 2002-12-23 2005-09-08 Wyeth Corp Anticuerpos contra pd-1, y sus usos.
US7459154B2 (en) 2002-12-26 2008-12-02 Cell Genesys, Inc. Methods and reagents for the enhancement of virus transduction in the bladder epithelium
MXPA05007019A (es) 2002-12-30 2005-08-18 Amgen Inc Terapia de combinacion con factores co-estimuladores.
US20040197312A1 (en) 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
US20050282280A1 (en) 2003-08-28 2005-12-22 Ennist David L Oncolytic adenoviral vectors encoding GM-CSF
US20050186178A1 (en) 2003-08-28 2005-08-25 Ennist David L. Oncolytic adenoviral vectors encoding GM-CSF
AU2003265873A1 (en) 2003-08-28 2005-04-14 Cell Genesys, Inc. Oncolytic adenoviral vectors encoding gm-csf
US7473418B2 (en) 2004-03-25 2009-01-06 Cell Genesys, Inc. Pan cancer oncolytic vectors and methods of use thereof
TW200607859A (en) 2004-08-23 2006-03-01 Cell Genesys Inc Oncolytic adenoviral vectors encoding GM-CSF
US20060062764A1 (en) 2004-08-25 2006-03-23 Seshidar-Reddy Police Fiber-modified adenoviral vectors for enhanced transduction of tumor cells
SI2650020T1 (sl) 2005-05-06 2017-03-31 Providence Health & Services - Oregon Technology Transfer Trimerični OX40 imunoglobulinski fuzijski protein in postopek za njegovo uporabo
GB0522476D0 (en) 2005-11-03 2005-12-14 Biovex Ltd Oncolytic herpes virus vectors
WO2007112316A2 (en) 2006-03-24 2007-10-04 Morton Donald L Mycobacterial immunotherapy for cancer treatment
EP2013348A4 (en) 2006-03-30 2009-09-02 Univ California METHOD AND COMPOSITIONS FOR LOCALIZED SECRETION OF ANTI-CTLA-4 ANTIBODIES
US7919079B2 (en) 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
BRPI0720724A2 (pt) 2006-12-27 2014-04-01 Univ Emory Composições e métodos para o tratamento de infecções e tumores
US8840881B2 (en) 2008-08-28 2014-09-23 Aduro Gvax Inc. Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancer
US9345787B2 (en) 2008-12-22 2016-05-24 Targovax Oy Adenoviral vectors and methods and uses related thereto
BRPI0924123B8 (pt) 2008-12-22 2021-05-25 Oncos Therapeutics Oy vetores adenovirais oncolíticos, usos dos mesmos, composição farmacêutica e método para produzir gmcsf em uma célula in vitro
PL3241435T3 (pl) 2009-07-08 2021-12-13 Kymab Limited Modele zwierzęce i cząsteczki terapeutyczne
JP2014500004A (ja) 2010-09-24 2014-01-09 オンコス セラピュティックス オサケ ユキチュア 抗ｃｔｌａ−４モノクローナル抗体をコードする腫瘍溶解性アデノウイルスベクター
US9056133B2 (en) 2011-05-25 2015-06-16 Cti-S.A. Pharmaceutical kit and method for treating cancer
CA2862390A1 (en) 2012-01-25 2013-08-01 Dnatrix, Inc. Biomarkers and combination therapies using oncolytic virus and immunomodulation
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
KR20150038066A (ko) 2012-07-30 2015-04-08 알렉스 와 힌 영 종양 세포, 암세포파괴 바이러스 벡터 및 면역 체크포인트 조절인자를 갖는 암 백신 시스템
DK3461491T3 (da) 2013-04-18 2025-02-03 Tilt Biotherapeutics Oy Forbedret adoptiv celleterapi
CN114317461A (zh) 2013-11-22 2022-04-12 德那翠丝有限公司 表达免疫细胞刺激受体激动剂的腺病毒
CA2955084C (en) 2014-07-16 2023-08-29 Transgene Sa Combination of oncolytic virus with immune checkpoint modulators
US9988452B2 (en) 2014-10-14 2018-06-05 Novartis Ag Antibody molecules to PD-L1 and uses thereof
WO2016145354A1 (en) * 2015-03-12 2016-09-15 Viventia Bio Inc. Dosing strategies for targeting epcam positive bladder cancer
JP6954648B2 (ja) 2015-10-19 2021-10-27 シージー オンコロジー， インコーポレイテッド 併用療法による固形腫瘍又はリンパ系腫瘍の治療方法
US11497781B2 (en) 2016-03-10 2022-11-15 Cg Oncology, Inc. Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor
AU2018251987B2 (en) 2017-04-14 2024-11-28 Cg Oncology, Inc. Methods of treating bladder cancer

Also Published As

Publication number Publication date
JP2022164776A (ja) 2022-10-27
AU2018251987B2 (en) 2024-11-28
US12370229B2 (en) 2025-07-29
CN110573624A (zh) 2019-12-13
EP4599893A2 (en) 2025-08-13
US11596660B2 (en) 2023-03-07
JP2020516590A (ja) 2020-06-11
US11338003B2 (en) 2022-05-24
EP3610026B1 (en) 2025-05-14
EP4599893A3 (en) 2025-11-05
EP3610026A1 (en) 2020-02-19
NZ759184A (en) 2025-06-27
AU2018251987A1 (en) 2019-12-05
EP3610026A4 (en) 2021-03-24
WO2018191654A1 (en) 2018-10-18
US20220331384A1 (en) 2022-10-20
KR20190134786A (ko) 2019-12-04
JP7597384B2 (ja) 2024-12-10
US20220296658A1 (en) 2022-09-22
JP2024028541A (ja) 2024-03-04
ES3030923T3 (en) 2025-07-02
US20210085734A1 (en) 2021-03-25

Similar Documents

Publication Publication Date Title
PL3610026T3 (pl) Cg0070 do leczenia raka pęcherza moczowego in situ opornego na bcg
IL272596A (en) Pridopidine for use in the treatment of ALS
IL282663A (en) BT1718 for use in cancer treatment
IL271221A (en) Antibodies that bind il-1beta for use in cancer therapy
SG11201801742XA (en) Treated surface steel
GB201715123D0 (en) FlyLogix Big Book
IL271019A (en) Tinostemustine for the treatment of ovarian cysts
SG11201610551TA (en) Combinations for treating cancers
GB2564535B (en) Valve apparatus
GB2566465B (en) Valve apparatus
IL262143A (en) Improvements in cancer treatment
GB201704603D0 (en) Drainage apparatus
PT3250218T (pt) Péptido natkide para o tratamento da obesidade
ES3046669T3 (en) Neospora for use in treating cancer
GB2547803B (en) Treatment mat
SMT202100667T1 (it) Metodi per trattare il cancro ovarico
GB201711007D0 (en) Bladder
GB2578008B (en) 1-Acetyl-5-Nitro-4-Phenyl-3-Pyrrolin-2-one for use in cancer treatment
ZA201807955B (en) Method maintaining iron homeostasis with shogaols
GB201720177D0 (en) Drainage apparatus
GB201718936D0 (en) Drainage apparatus
GB201609808D0 (en) In situ woodwind pad
GB201800055D0 (en) Improvements in Capacitoirs
GB201617451D0 (en) Polypeptides for use in therapy
GB201612247D0 (en) Drainage apparatus